Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment-Reference-Cited by-同舟云学术

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment

Published:2018-03-01 Issue:3 Volume:136 Page:257
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Bressler Neil M.¹,Beaulieu Wesley T.²,Glassman Adam R.²,Blinder Kevin J.³,Bressler Susan B.¹,Jampol Lee M.⁴,Melia Michele²,Wells John A.⁵,

Affiliation:

1. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland

2. Jaeb Center for Health Research, Tampa, Florida

3. The Retina Institute, St Louis, Missouri

4. Feinberg School of Medicine, Northwestern University Medical School, Chicago, Illinois

5. Palmetto Retina Center, Columbia, South Carolina

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Cited by 237 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis;Journal of VitreoRetinal Diseases;2024-09-14

2. Effect of anti-vascular endothelial growth factor on early-stage post-vitrectomy macular edema in patients with proliferative diabetic retinopathy;BMC Ophthalmology;2024-09-06

3. Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group;European Journal of Ophthalmology;2024-09-05

4. Diabetic Macular edema;Diabetic Retinopathy - Advancement in Understanding the Pathophysiology and Management Strategies [Working Title];2024-07-22

5. Prediction of Long-Term Treatment Outcomes for Diabetic Macular Edema Using a Generative Adversarial Network;Translational Vision Science & Technology;2024-07-03